WO2012040258A3 - Therapeutic piperazines - Google Patents

Therapeutic piperazines Download PDF

Info

Publication number
WO2012040258A3
WO2012040258A3 PCT/US2011/052441 US2011052441W WO2012040258A3 WO 2012040258 A3 WO2012040258 A3 WO 2012040258A3 US 2011052441 W US2011052441 W US 2011052441W WO 2012040258 A3 WO2012040258 A3 WO 2012040258A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
therapeutic
piperazines
function
disorders
Prior art date
Application number
PCT/US2011/052441
Other languages
French (fr)
Other versions
WO2012040258A2 (en
Inventor
Alan Kaplan
Terence Keenan
Michael Weinhouse
Mark Wilson
Andrew Lindstrom
William Ripka
Mi Chen
Original Assignee
Helicon Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helicon Therapeutics, Inc. filed Critical Helicon Therapeutics, Inc.
Priority to EP11827395.2A priority Critical patent/EP2643000A4/en
Publication of WO2012040258A2 publication Critical patent/WO2012040258A2/en
Publication of WO2012040258A3 publication Critical patent/WO2012040258A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

The invention includes a compound of formula I... wherein R1, Y, A, n, R4 and Z have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function and/or treating cognitive disorders or impariment, traumatic and/or ischemic injuries of the central and peripheral nervous system and/or psychiatric disorders in animals, especially humans.
PCT/US2011/052441 2010-09-22 2011-09-21 Therapeutic piperazines WO2012040258A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11827395.2A EP2643000A4 (en) 2010-09-22 2011-09-21 Therapeutic piperazines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/887,920 US8927546B2 (en) 2006-02-28 2010-09-22 Therapeutic piperazines
US12/887,920 2010-09-22

Publications (2)

Publication Number Publication Date
WO2012040258A2 WO2012040258A2 (en) 2012-03-29
WO2012040258A3 true WO2012040258A3 (en) 2012-06-07

Family

ID=45874337

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/052441 WO2012040258A2 (en) 2010-09-22 2011-09-21 Therapeutic piperazines

Country Status (3)

Country Link
US (2) US8927546B2 (en)
EP (1) EP2643000A4 (en)
WO (1) WO2012040258A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG171635A1 (en) * 2006-02-28 2011-06-29 Helicon Therapeutics Inc Therapeutic piperazines as pde4 inhibitors
US8710062B2 (en) 2011-03-11 2014-04-29 Taipei Medical University Piperazinedione compounds
US9198432B2 (en) * 2011-08-11 2015-12-01 Bayer Intellectual Property Gmbh 1,2,4-triazolyl-substituted ketoenols
CN102603676B (en) * 2012-02-20 2014-02-12 徐江平 Phosphodiesterase 4 inhibitor capable of avoiding vomiting reaction
KR102067850B1 (en) 2012-05-17 2020-01-17 어레이 바이오파마 인크. Process for making hydroxylated cyclopentylpyrimidine compounds
CA2873658C (en) 2012-05-17 2021-01-26 Genentech, Inc. Process for making amino acid compounds
US9309204B2 (en) 2012-05-17 2016-04-12 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
CA2873661C (en) 2012-05-17 2020-07-21 Genentech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
KR20220143143A (en) 2012-05-17 2022-10-24 제넨테크, 인크. Amorphous form of an akt inhibiting pyrimidinyl - cyclopentane compound, compositions and methods thereof
DK2878594T3 (en) * 2012-07-27 2019-02-04 Sato Pharma DIFLUOROMETHYLENE COMPOUND
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
CN106632124B (en) * 2016-11-30 2019-02-05 西安近代化学研究所 The synthetic method of 5,5 '--3,3 '-connection -1,2,4- oxadiazoles of ethyl diacetate base
EP3548034A4 (en) * 2016-12-05 2020-07-08 Microbiotix, Inc. Broad-spectrum inhibitors of filoviruses

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007100852A1 (en) * 2006-02-28 2007-09-07 Helicon Therapeutics, Inc. Therapeutic piperazines as pde4 inhibitors
US20100056604A1 (en) * 2000-11-02 2010-03-04 Research Foundation Of The City University Of New York Methods for stimulating nervous system regeneration and repair by inhibiting phosphodiesterase type iv

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2996507A (en) 1959-09-09 1961-08-15 Abbott Lab Piperazine compounds
US3306903A (en) 1965-10-07 1967-02-28 Council Scient Ind Res 1-aminopyridyl-4-(phenyl or pyridyl)-piperazines and intermediates
FR2262964B1 (en) 1973-04-05 1978-07-28 Synthelabo
AT330777B (en) 1973-09-08 1976-07-26 Thomae Gmbh Dr K PROCESS FOR THE PREPARATION OF NEW ISOCHINOLINE DERIVATIVES AND THEIR SALTS
DE2345422C2 (en) 1973-09-08 1983-12-22 Dr. Karl Thomae Gmbh, 7950 Biberach Substituted isoquinolyl-arylpiperazines containing these drugs and processes for their preparation
GB1575904A (en) 1976-04-23 1980-10-01 Lilly Industries Ltd Phenyl piperazines
US4093726A (en) 1976-12-02 1978-06-06 Abbott Laboratories N-(2-benzimidazolyl)-piperazines
US4666911A (en) 1981-07-14 1987-05-19 Taiho Pharmaceutical Company Limited Allophanoylpiperazine compound and analgesic composition containing same as active ingredient
FR2551753B2 (en) 1982-09-22 1986-02-28 Lipha BENZOTRIAZINE-1,2,3-ONES-4, PROCESS FOR THE PREPARATION AND MEDICAMENTS CONTAINING THEM
DE3442860A1 (en) 1984-11-24 1986-05-28 Kali-Chemie Pharma Gmbh, 3000 Hannover 5-ALKYL-1-PHENYL-2-PIPERAZINOALKYLPYRAZOLINE-3-ON COMPOUNDS AND METHODS AND INTERMEDIATE PRODUCTS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
US4845100A (en) 1985-04-12 1989-07-04 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof, processes for preparing the same and cardiotonic composition containing the same
US4960776A (en) 1987-01-28 1990-10-02 A. H. Robins Company, Inc. 4-aryl-N-(alkylaminoalkyl, heterocyclicamino and heterocyclicamino)alkyl)-1-piperazinecarboxamides
US5086055A (en) 1990-12-24 1992-02-04 A. H. Robins Company, Incorporated Series of 5-[-(4-aryl-1-piperazinyl)alkyl]-2-oxazolidinone derivatives useful in the treatment of allergic conditions
MX9202022A (en) 1991-05-01 1992-11-01 Otsuka Pharma Co Ltd DERIVATIVES OF PIRAZINE AND PROCESS FOR ITS PREPARATION.
FR2680172B1 (en) 1991-08-05 1993-11-19 Fabre Medicament Pierre NEW SUBSTITUTED PIPERAZINYLALCOYL-3 DIHYDRO-2,3 4H-BENZOXAZINE-1,3 ONES-4, THEIR PREPARATION AND THERAPEUTIC APPLICATION.
WO2001054650A2 (en) 2000-01-31 2001-08-02 Panmedix Incorporated Measuring pharmaceutical cognitive impairment
US7087015B1 (en) 2000-01-31 2006-08-08 Panmedix, Inc. Neurological pathology diagnostic apparatus and methods
US6964638B2 (en) 2000-01-31 2005-11-15 Pan Medix, Inc. Measuring cognitive impairment
CA2402384A1 (en) 2000-03-16 2001-09-20 Inflazyme Pharmaceuticals Ltd. Benzylated pde4 inhibitors
AU2001231083A1 (en) 2000-03-27 2001-10-08 Panmedix Incorporated Measuring cognitive impairment
CA2448080A1 (en) 2001-05-22 2002-11-28 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues
AU2002326948A1 (en) 2001-09-18 2003-04-01 Bristol-Myers Squibb Company Piperizinones as modulators of chemokine receptor activity
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
WO2004024728A2 (en) 2002-09-16 2004-03-25 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as phosphodiesterase inhibitors
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0322510D0 (en) 2003-09-25 2003-10-29 Glaxo Group Ltd Novel compounds
US7429666B2 (en) 2004-06-10 2008-09-30 Merck Frosst Canada Ltd. Pyridine analogs as C5a antagonists
GT200600042A (en) 2005-02-10 2006-09-27 Aventis Pharma Inc BIS ARILO AND HETEROARILO COMPOUNDS REPLACED AS SELECTIVE ANTAGONISTS OF 5HT2A
EP1874781B9 (en) 2006-04-19 2010-09-08 Boehringer Ingelheim International GmbH Dihydrothienopyrimidines for the treatment of inflammatory diseases
BRPI0812347A2 (en) * 2007-06-08 2016-08-02 Helicon Therapeutics Inc compound, pharmaceutical composition and methods of modulating one or more gabaa subtypes, enhancing cognitive function and treating cognitive dysfunction in animals and uses of the compound

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056604A1 (en) * 2000-11-02 2010-03-04 Research Foundation Of The City University Of New York Methods for stimulating nervous system regeneration and repair by inhibiting phosphodiesterase type iv
WO2007100852A1 (en) * 2006-02-28 2007-09-07 Helicon Therapeutics, Inc. Therapeutic piperazines as pde4 inhibitors

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DYM ET AL.: "Molecular Docking of Competitive Phosphodiesterase Inhibitors", MOL PHARMACOL, vol. 61, no. 20, 2002, pages 20 - 25, XP055081424, Retrieved from the Internet <URL:http://molpharm.aspetjournals.org/content/61/1/20.full.pdf> *
See also references of EP2643000A4 *

Also Published As

Publication number Publication date
WO2012040258A2 (en) 2012-03-29
US20150087645A1 (en) 2015-03-26
US8927546B2 (en) 2015-01-06
US20110065691A1 (en) 2011-03-17
EP2643000A2 (en) 2013-10-02
EP2643000A4 (en) 2014-05-21
US9624200B2 (en) 2017-04-18

Similar Documents

Publication Publication Date Title
WO2012040258A3 (en) Therapeutic piperazines
TW200744586A (en) Therapeutic compounds
MX2021013110A (en) Heterocyclic compounds as ret kinase inhibitors.
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
WO2015200680A8 (en) Prmt5 inhibitors and uses thereof
WO2014031438A3 (en) SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
IN2014MN02497A (en)
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
EP4104837A3 (en) Heterocyclic compounds as ret kinase inhibitors
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
WO2015095337A3 (en) PYRAZOLO[1,5-a]PYRIMIDINECARBOXAMIDE DERIVATIVES FOR TREATING COGNITIVE IMPAIRMENT
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
WO2008094737A3 (en) Purine compounds and compositions as kinase inhibitors for the treatment of plasmodium related diseases
UA108087C2 (en) Solid forms of n-(4-(7-azabicyclo[2.2.1]heptane-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide
WO2011025706A3 (en) Heterocyclic amide compounds as protein kinase inhibitors
MX2009004791A (en) 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors.
WO2013163244A8 (en) Imidazothiadiazole derivatives as protease activated receptor 4 (par4) inhibitors for treating platelet aggregation
WO2014091298A3 (en) Nitrogen containing morphinan derivatives and the use thereof
WO2014153100A3 (en) Arginine methyltransferase inhibitors and uses thereof
SG171635A1 (en) Therapeutic piperazines as pde4 inhibitors
HK1154002A1 (en) Imidazopyridazinecarbonitriles useful as kinase inhibitors
WO2013013815A8 (en) Substituted heteroaromatic pyrazole-containing carboxamide and urea derivatives as vanilloid receptor ligands
NZ702254A (en) 5-amino[1,4]thiazines as bace 1 inhibitors
WO2014128669A3 (en) Trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
WO2015100092A3 (en) 7-beta analogs of orvinols

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11827395

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2011827395

Country of ref document: EP